Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus CLINORIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus CLINORIL.
BUTAZOLIDIN vs CLINORIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, and antipyretic effects. Sulindac is a prodrug converted to the active sulfide metabolite.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
150-200 mg orally twice daily, with maximum daily dose of 400 mg.
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
7.8 hours (terminal); clinical context: prolonged in elderly and renal impairment, requiring dose adjustment.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Renal: 50% as unchanged drug, 25% as glucuronide conjugate; Biliary/Fecal: 25% as metabolites.
Category C
Category C
NSAID
NSAID